HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Martin, N. E. Articles by Barrett, J. S. Search for Related Content PubMed PubMed Citation Articles by Martin, N. E. Articles by Barrett, J. S. Social Bookmarking                         What's this?

Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers

From Aventis Pharmaceuticals, Bridgewater, New Jersey (Dr. N. E. Martin, Ms. Collison, Dr. L. L. Martin, Dr. Barrett) and Pharmaceutical Profiles Ltd., Nottingham, United Kingdom (Dr. Tardif, Dr. Wilding, Ms. Wray).

M100240 is the thioester of MDL 100,173, a dual angiotensin-converting enzyme (ACE)/neutral endopeptidase (NEP) inhibitor currently in phase II development. The purpose of this study was to evaluate the relative bioavailability of M100240 in various regions of the gastrointestinal tract using the Enterion^TM capsule, a noninvasive radiocontrolled device providing targeted drug delivery, to explore the absorption characteristics of M100240 in healthy volunteers. In addition, the absolute bioavailability of an immediate-release formulation of M100240 was assessed. Pharmacokinetic data were obtained from 13 healthy subjects in an open-label, single-dose, randomized, five-period crossover study. Treatments included 25 mg M100240 administered via short intravenous infusion, oral immediate-release tablet administration, and oral Enterion^TM capsule delivery of drug substance to the proximal small bowel, distal small bowel, and ascending colon. Each treatment was separated by a 14-day drug-free washout period. The localization of the Enterion^TM capsule in the gastrointestinal tract was monitored using scintigraphic imaging. M100240 and MDL 100,173 plasma concentrations were quantified using a validated LC/MS/MS method, and pharmacokinetic parameters were calculated using noncompartmental methods. The estimates of relative bioavailability in the proximal small bowel, distal small bowel, and ascending colon relative to the oral immediate-release tablet are approximately 94%, 97%, and 41%, respectively. M100240 is primarily absorbed throughout the proximal and distal small bowel with modest absorption in the ascending colon. The absolute bioavailability estimate of the M100240 immediate-release formulation is 49%. These data characterize the fundamental in vivo performance attributes of M100240, thereby providing an approach for optimizing prototype modified-release formulations for this compound.

Key Words: M100240 • MDL 100,173 • Enterion^TM • gastrointestinal tract • gamma scintigraphy • bioavailability

Address for reprints: Nancy E. Martin, PharmD, RPh, Clinical Manager, Global Biopharmaceuticals, DMPK, Aventis Pharmaceuticals, Route 202-206, P.O. Box 6800, Mailstop M303B, Bridgewater, NJ 08807.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Connor, P. Evans, J. Doto, C. Ellis, and D. E. Martin An Oral Human Drug Absorption Study to Assess the Impact of Site of Delivery on the Bioavailability of Bevirimat J. Clin. Pharmacol., May 1, 2009; 49(5): 606 - 612. [Abstract] [Full Text] [PDF]

				P. H. Hinderling, A. H. Karara, B. Tao, M. Pawula, I. Wilding, and M. Lu Systemic Availability of the Active Metabolite Hydroxy-Fasudil After Administration of Fasudil to Different Sites of the Human Gastrointestinal Tract J. Clin. Pharmacol., January 1, 2007; 47(1): 19 - 25. [Abstract] [Full Text] [PDF]

				I. Cirillo, N. E. Martin, B. Brennan, and J. S. Barrett The Effect of Food on the Pharmacokinetics of a Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240 J. Clin. Pharmacol., December 1, 2004; 44(12): 1379 - 1384. [Abstract] [Full Text] [PDF]